SCHEMBL15764707

SCHEMBL15764707

CN(C(=O)c1ccc(F)cc1)c1ccn2ncc(-c3ccc(CF)cc3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLNR O43193 6/20 0.41
RET P07949 2/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
MCHR1 Q99705 1/20 0.36
GRIN2B Q13224 1/20 0.35
ITK Q08881 1/20 0.35
NSD2 O96028 1/20 0.35
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ROCK1 Q13464 1/20 0.34
PDE10A Q9Y233 1/20 0.34
GRM2 Q14416 1/20 0.34
HSD17B1 P14061 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17309060 0.91 MAPK14 (0.38) MLNRRETALDH1A1MCHR1ITK
SCHEMBL17309067 0.90 MLNR (0.41) MLNRRETALDH1A1GRIN2BKDM4E
SCHEMBL15717718 0.88 RET (0.43) MLNRRETALDH1A1CYP1A2CYP3A4
SCHEMBL15764752 0.88 CAMKK1 (0.36) MLNRRETMCHR1PDE10A
SCHEMBL15764753 0.87 MLNR (0.42) MLNRRETMCHR1GRIN2BGRM2
SCHEMBL15717246 0.86 MCHR1 (0.40) MLNRRETALDH1A1CYP1A2CYP3A4
SCHEMBL15764708 0.85 CSF1R (0.37) MLNRRET
SCHEMBL15764710 0.84 MLNR (0.40) MLNRRETMCHR1
SCHEMBL19996175 0.84 S1PR1 (0.37) MLNRRETALDH1A1CYP1A2CYP3A4
SCHEMBL15717869 0.82 NPC1 (0.39) MLNRRETALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556169-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2017-01-31 US disclosed
US-20160333012-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2016-11-17 US disclosed
US-20150344471-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2015-12-03 US disclosed
US-20150011522-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2015-01-08 US disclosed
US-8871754-B2 Compounds and compositions for the treatment of parasitic diseases IRM LLC (BM) 2014-10-28 US disclosed
US-20140155367-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2014-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344471-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES MAPT, CYP11B1, CYP11B2 MLNR 2852/4885RET 2162/4885ALDH1A1 1143/4885
US-20150011522-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES MAPT, CYP11B1, CYP11B2 MLNR 2852/4885RET 2162/4885ALDH1A1 1143/4885
US-20140155367-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES MAPT, CYP11B1, CYP11B2 MLNR 2852/4885RET 2162/4885ALDH1A1 1143/4885
US-20160333012-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES MAPT, CYP11B1, CYP11B2 MLNR 2852/4885RET 2162/4885ALDH1A1 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.